Evidence map›Paper›PMID 32774442›Full record

ReviewAnnals of general psychiatry2020

The role of shared decision-making in improving adherence to pharmacological treatments in patients with schizophrenia: a clinical review.

Andrea Fiorillo, Stefano Barlati, Antonello Bellomo, Giulio Corrivetti, Giuseppe Nicolò, Gaia Sampogna, Valentina Stanga, Franco Veltro, Giuseppe Maina, Antonio Vita

Abstract readReview
In one paragraph

Review in Annals of general psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
57citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

57 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Association between Exposure to Statin Choice and Adherence to Statins: An Observational Cohort Study.Medical decision making : an international journal of the Society for Medical Decision Making · 2025
    Observational
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Andrea FiorilloDepartment of Psychiatry, University of Campania "L. Vanvitelli, Largo Madonna delle Grazie, Naples, Italy.
Stefano BarlatiDepartment of Mental Health and Addiction Services, ASST Spedali Civili, Brescia, Italy.
Antonello BellomoDepartment of Clinical and Experimental Medicine, Psychiatric Unit, University of Foggia, Foggia, Italy.
Giulio CorrivettiDepartment of Mental Health, Salerno, Italy.
Giuseppe NicolòDepartment of Mental Health Colleferro, ASL Roma G, Tivoli, Italy.
Gaia SampognaDepartment of Psychiatry, University of Campania "L. Vanvitelli, Largo Madonna delle Grazie, Naples, Italy.
Valentina StangaDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Franco VeltroMental Health Department of Campobasso, Campobasso, Italy.
Giuseppe MainaDepartment of Neuroscience, University of Torino, Turin, Italy.
Antonio VitaDepartment of Mental Health and Addiction Services, ASST Spedali Civili, Brescia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shared decision-making (SDM) is a process in which the doctor provides clear and complete medical information to patients about their treatment, and patients provide information on his/her preferences. Patients and clinicians bring different, but equally important, knowledge to the decision-making process. Through the adoption of SDM, it should be possible to overcome the barriers that hinder the acceptance of long-acting injectable antipsychotics (LAIs) by patients, and often also by psychiatrists. The present paper is a critical appraisal of recent literature on the impact of SDM in improving adherence to pharmacological treatments and in implementing the use of LAIs in the treatment of patients with schizophrenia. SDM is recognized as a promising strategy to improve collaboration between clinicians and patients in achieving recovery. When considering drug treatments, clinicians must evaluate the patient's preferences, expectations and concerns towards the development of a personalized treatment strategy. Moreover, an active involvement in the decision process could reduce the patient's perception of being coerced into the use of LAIs. Involving patients in the choice of therapy is not sufficient to increase pharmacological adherence if, at the same time, there is no constant work of comparison and communication with the reference psychiatric team. SDM can be particularly effective for LAI prescription, since patient can have prejudices and unjustified fears related to the LAI formulation, which the doctor must resolve.

Indexed as

AdherenceEmpowermentLong-acting injectable antipsychoticsRecoverySchizophreniaShared decision-making

Identifiers

PMID32774442
PMCPMC7409631

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.